Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
Date:2/14/2012

ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and twelve months ended December 31, 2011.

Key Highlights:

  • Initial clinical data in the RESET study revealed potential of tasimelteon to reset the body clock in Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder).  
  • The tasimelteon Non-24-Hour Disorder program continues to advance towards a projected mid-2013 New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA).  Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012.
  • The tasimelteon MAGELLAN Phase IIb/III efficacy study for Major Depressive Disorder (MDD) is ongoing and Vanda expects to report top-line results in the first half of 2013.
  • Vanda recorded fourth quarter 2011 revenue of $8.4 million including royalties of $1.6 million.  Full year 2011 Fanapt® prescriptions, as reported by IMS, exceeded 120,000, compared to approximately 55,000 for 2010.

  • FULL YEAR 2011 REPORTED RESULTSTotal revenues for the full year 2011 were $31.3 million, compared to $35.7 million for 2010.  Full year 2011 revenues included $4.5 million in Fanapt® royalties received from Novartis, as compared to $3.1 million for the prior year.   Both 2011 and 2010 revenues include $26.8 million recognized from the $200.0 million upfront payment previously received from Novartis for Fanapt® U.S. and Canadian rights.  2010 full year revenues also included $5.8 million in product sales to Novartis and grant revenue.

    Total operating expenses for 2011 were $
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
    (Date:9/19/2014)... -- Over 200 runners participated in the fifth annual 5K ... Institute (ROI), hosted by Radiation Business Solutions. This year the ... Francisco.  "Donations are still coming in," ... Solutions, "but at this point, through registrations and ... ROI this year. This surpasses last year,s record of ...
    (Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014 ... a provider of advanced cancer genome analysis and ... leader in discovering and developing highly selective kinase ... first-ever comprehensive genomic study of malignant mixed Mullerian ... the female reproductive system, also known as carcinosarcoma. ...
    Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
    ... PARIS , June 3, 2010 ... together global,forces in personalised medicine, has today announced the ... personalised healthcare, as Executive,Director and board member. Dr. Bruinvels ... with the board of directors, for building,its strategic framework ...
    ... RESEARCH TRIANGLE PARK, N.C. , June 2 ... announced that it has received a letter from the ... labeling for its respiratory products Serevent® and Advair®.  The ... FDA advisory committee meetings regarding the safety profile of ...
    Cached Medicine Technology:EPEMED, the European Personalised Medicine Association, Appoints Executive Director 2EPEMED, the European Personalised Medicine Association, Appoints Executive Director 3GSK Announces Revised Product Labels for Serevent® and Advair® 2
    (Date:9/20/2014)... 2014 The print component of ... of the Calgary Herald, with a circulation of ... 270,000. The digital component is distributed nationally through ... network of top news sites and partner outlets. ... visit http://www.worklifebalanceinfo.ca . , The publication features ...
    (Date:9/20/2014)... (PRWEB) September 20, 2014 The festival season ... busy selling its newly released luxurious cocktail dresses . ... company has recently decided to launch a new promotion for ... is offered with a discounted price, from 20 to 71 ... a wide range of choices. They are provided in many ...
    (Date:9/20/2014)... (PRWEB) September 20, 2014 iFitDress.com, the ... gowns for women, has recently unveiled its new collection ... big sale for special offer on these new outfits; ... shopping season. All customers can now buy cheap ... The company’s sales representative says, “We have extensive experience ...
    (Date:9/20/2014)... September 20, 2014 "As a nurse, patients ... tanks," said an inventor from Tamaqua, Pa. "The reason that ... the backs of their chairs. My invention enables them to ... Kam Oxygen Sensor to make it easier to monitor the ... user knows when the tank is low. It allows changeovers ...
    (Date:9/20/2014)... September 20, 2014 QueenBeeTickets.com is ready ... star’s tour performances. She will visit many cities in ... until the 16th of April. , Click Here ... Tour tickets at QueenBeeTickets.com. , The star’s fans are ... see their favorite young singer in a live performance. ...
    Breaking Medicine News(10 mins):Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2
    ... of an initiative to give back to the cancer ... meetings, the American Society for Radiation Oncology (ASTRO) is ... of cancer survivorship issues., Gilda,s Club South Florida will ... exhibit at ASTRO,s 53rd Annual Meeting, scheduled for October ...
    ... (Sept. 1, 2011) Patients often take drugs to ... develop ulcers from taking their anti-inflammatory drugs for conditions ... major problems for their small intestines, McMaster researchers have ... Digestive Health Research Institute has found those stomach acid-reducing ...
    ... THURSDAY, Sept. 1 (HealthDay News) -- Strokes are on ... report shows. The number of people aged 15 to ... 1995 and 2008, say researchers from the U.S. Centers for ... to the increasing numbers of young people who have diseases ...
    ... with ALK-rearranged non-small cell lung cancer (NSCLC) responded ... patients whose cancer did not show ALK translocation, ... of the Journal of Thoracic Oncology, the official ... of Lung Cancer (IASLC). Lung adenocarcinoma can ...
    ... researchers have successfully injected cultured red blood cells (cRBCs) created ... according to study results published today in ... Society of Hematology (ASH). As the global need for ... is decreasing, these study results provide hope that one day ...
    ... Sept. 1 (HealthDay News) -- Researchers report that they used ... successfully injected the blood cells back into the human donor ... The findings raise the possibility of creating individualized blood supplies ... they need a transfusion, a potentially dicey situation if someone ...
    Cached Medicine News:Health News:Strokes Rising Among Teens, Young Adults: CDC 2Health News:Strokes Rising Among Teens, Young Adults: CDC 3Health News:Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows 2Health News:Researchers successfully perform first injection of cultured red blood cells in human donor 2Health News:Scientists Use Stem Cells for Blood 'Self-Transfusion' 2
    ... is an ultra-high speed, high resolution optical ... retina imaging and analysis. It ... Optical Coherence technology just emerging from clinical ... The ultra-high speed and high resolution ...
    ... Experience the finest surgical-quality loupes ... set the standard for innovative optical ... customer support. Delivering optimum performance with ... clear choice for medical professionals worldwide. ...
    ... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... performance with maximum comfort, SheerVision loupes ... professionals worldwide. All SheerVision loupes come ...
    ... SheerVision manufactures its signature line of award-winning ... Frame. These next generation loupes feature ... design, and are multi-coated lens for anti-glare, ... SV Sport frame offers a stylish, yet ...
    Medicine Products: